Strategic Communication and Public Relations

Defective tumor suppressor leads to leukemia - by an indirect route

No. 53c | 24/10/2013 | by Koh

Cancer often arises as a result of defects in genes known as tumor suppressors that inhibit cell growth. Scientists at the German Cancer Research Center (DKFZ) have studied how the loss of a tumor suppressor called PTEN leads to the development of leukemia. They were surprised to discover that the absence of PTEN does not cause blood stem cells themselves to divide excessively. Instead, leukemia develops as a result of the overproduction of a chemical messenger (G-CSF) in granulocytes that causes blood stem cells to leave the bone marrow and migrate into the spleen, where this causes an out-of-control multiplication of white blood cells.

Model of PTEN. Picture: Hypomorph, Wikimedia Commons

Genetic defects that lead to cancer can basically be classified in two groups: defects that turn growth-promoting genes into permanently activated “cancer genes” (oncogenes), and defects that cause a growth-inhibiting gene, or tumor suppressor, to lose its functions.

Every cell contains multiple tumor suppressors; some have been found to undergo mutations in numerous types of cancers. One of these is the phosphatase PTEN, an enzyme which is often defective in cancers such as glioblastoma, prostate cancer and leukemia. In these cases it loses its capacity to repress growth and promotes the development of cancer.

“We always believed that a PTEN defect causes blood stem cells in the bone marrow to divide infinitely, and that this leads to leukemia,” says Prof. Andreas Trumpp, a stem cell expert. Trumpp is head of DKFZ’s Division of Stem Cells and Cancer and director of the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), which is supported by the Dietmar Hopp Foundation and DKFZ.

To verify this hypothesis, Melania Tesio, a coworker in Trumpp’s laboratory, bred mice in whose cells the scientists could “switch off” the production of PTEN in blood stem cells and their descendants. Animals whose PTEN production had been turned off developed enlarged spleens and showed signs of a precancerous phase of leukemia known as myeloproliferative syndrome. Ultimately they developed various types of blood cancer.

The researchers were surprised, however, to find that cell division in the blood stem cells was not increased, as they had expected. Instead, they discovered that levels of a cellular messenger called G-CSF (granulocyte colony-stimulating factor) were much higher than normal. This messenger, which is also produced in small amounts in the granulocytes of normal animals, is known to “mobilize” blood stem cells; they leave the bone marrow and migrate through the body. This is exactly what happened in PTEN-negative animals: Blood stem cells leave the bone marrow and settle in the spleen.

Is the excessive production of G-CSF really responsible for the migration of blood stem cells into the spleen? The DKFZ researchers examined this in experiments with mice whose cells are unable to produce both PTEN and G-CSF. In these animals, blood stem cells remained in the bone marrow, and the animals did not develop myeloproliferative syndrome.

“This proves that the overproduction of G-CSF in PTEN-mutated granulocyte cells is what causes blood stem cells to migrate,” says Andreas Trumpp. “G-CSF not only mobilizes stem cells, but also has an effect on the granulocyte cells themselves by inducing them to divide. This double effect on stem cells and granulocytes sets off the progression toward leukemia. The disease therefore develops along an indirect path, rather than by a defect in the PTEN tumor suppressor that drives stem cells to multiply, as previously assumed.”

Melania Tesio, Gabriela M. Oser, Irène Baccelli, William Blanco-Bose, Hong Wu, Joachim R. Göthert, Scott C. Kogan, and Andreas Trumpp: Pten loss in the bone marrow leads to G-CSF–mediated HSC mobilization. Journal of Experimental Medicine 2013, DOI: doi:10.1084/jem.20122768

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS